In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals.
The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992.
Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.
All content for Oncology Times Broadcast News is the property of Oncolgy Times & Audio Medica and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals.
The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992.
Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.
Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer
Oncology Times Broadcast News
9 minutes 5 seconds
16 years ago
Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer
Oncology Times Broadcast News:
Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer
For adjuvant treatment of stage II and stage III colorectal cancer the vascular endothelial growth factor (VEGF) receptor inhibitor, bevacizumab, gave no benefit in disease-free survival after a median follow up of three years when added to standard oxaliplatin-based chemotherapy in the NSABP C-O8 phase III study reported at the 2009 ASCO meeting held in Orlando, Florida .
Lead author Dr Norman Wolmark MD Chair of the National Surgical Adjuvant Breast and Bowel Project, and Chair of the Department of Oncology at Allegheny General Hospital in Pittsburgh, said in an interview with Peter Goodwin: "These data do not support using bevacizumab in the adjuvant setting."
Oncology Times Broadcast News
In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals.
The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992.
Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.
